Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apomorphine nasal powder for acute off episodes in Parkinson's disease
2006-000391-32Phase 3Completed
- Sponsor
- Britannia Pharmaceuticals
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (2 arms), sponsored by Britannia Pharmaceuticals. Primary endpoints: Time to initial improvement in acute off episode, Safety and local tolerability over 12 weeks and 1 more. Started Apr 2006; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-000391-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000391-32.